Trials / Completed
CompletedNCT04493255
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Eisai Limited · Industry
- Sex
- Male
- Age
- 35 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to determine the pharmacokinetics (PK) and excretion of E7090 and its metabolites in healthy male participants. Also, to assess the safety and tolerability of a single dose of E7090 in healthy male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]E7090 | \[14C\]E7090, oral capsule. |
Timeline
- Start date
- 2020-09-09
- Primary completion
- 2020-10-21
- Completion
- 2020-10-21
- First posted
- 2020-07-30
- Last updated
- 2021-02-04
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04493255. Inclusion in this directory is not an endorsement.